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S334 Poster Session IIGVHD scores were: PC-1 (n5 5): 660.7; NC-1 (n5 4): 0; NC-2 (n
5 4): 0; TLI/ATS (n5 4): 0.460.8; TLI-FTS/ATS (n5 7): 4.560.9,
with similar patterns in liver. Day 6 target organ accumulation of
H-2Kb+CD4+Foxp3+ Treg was markedly decreased (p\ 0.05) and
H-2Kb+CD8+ cells increased (p \ 0.01) in TLI-FTS/ATS hosts.
In conclusion, shielding from thymic irradiation alone ablates
tolerance after TLI/ATS + BMT, indicating that recurrent thymic
radiation exposure in the non-myeloablative setting enhances rather
than impedes early immune mechanisms leading to transplantation
tolerance in this regimen.We are currently delineating novel thymic
pathways of enhanced immunoregulatory cell selection in thymic-
irradiation-induced transplant tolerance after TLI/ATS + BMT.503
HOST MYELOID-DERIVED SUPPRESSOR CELLS INDUCE DONOR TREG
PROLIFERATION AND TRANSPLANTATION TOLERANCE VIA IL-4Ra/
STAT6 AFTER TLI/ATS NON-MYELOABLATIVE BMT
Van Der Merwe, M.1, Ong, T.1, Vogel, P.2, Pillai, A.1 1St. Jude Child-
ren’s Research Hospital, Memphis, TN; 2St. Jude Children’s Research
Hospital, Memphis, TN
Murine total Lymphoid Irradiation and rabbit Anti-Thymocyte
Serum (TLI/ATS) non-myeloablative conditioning has been trans-
lated for tolerance induction to facilitate engraftment without lethal
GVHD after allogeneic HSCT.Tolerance is mediated by host IL-4-
induced expansion of donor CD4+Foxp3+ Treg from the unmanipu-
lated graft (Pillai et al, Blood 2009). To delineate mechanisms of
IL-4-dependent donor Treg expansion, wild-type (WT) BALB/c
(H-2d) hosts were given 3 doses ATS + 17 doses (240 cGy each)
TLI and infusion of 50 x 106 bone marrow and 60 x 106 CFSE-la-
beled splenocytes (BMT) from WT or STAT6-/- C57BL/6 (H-2b)
donors. Control WT BALB/c were given 800 cGy single-dose total
body irradiation (TBI) with either 50 x 106 bone marrow alone (neg-
ative control, NC-1) or 50 x 106 bone marrow + 60 x 106 splenocytes
(positive control, PC) from WT C56BL/6 donors. Day 6 H-
2Kb+TCR+CD8+ cell accumulation in spleen, liver and colon were
potently inhibited, and H-2Kb+CD4+Foxp3+ Treg proliferation
maintained, after STAT6-/- donor BMT, indicating that host IL-4
effects on donor Treg proliferation is indirect. By contrast, IL-
4Ra-/- BALB/c hosts receiving TLI/ATS+BMT developed dramatic
lethal acuteGVHD [day 6 colonicGVHDscores: PC (n5 5) 660.8;
NC-1 (n 5 5): 0; WT TLI/ATS (n5 10): 1.3 60.9; IL-4Ra-/-TLI/
ATS (n 5 10): 5.8 61.3]. We delineated 2 subsets of IL-4Ra/
CD124hi cells [CD11b+Gr-1Ghi (M1) and CD11b+Gr-1Gint (M2)]
that dominate the host myeloid compartment in WT hosts at both
day 0 after TLI/ATS and day 6 after TLI/ATS + BMT vs TBI/
ATS or TBI/ATS + BMT (p\ 0.05). Both M1 and M2 subsets are
F4/80negCD115negB220negCD11cnegCD1dhi myeloid derived sup-
pressor cells (MDSC), immature marrow-derived cells which are ab-
lated after lethal or sublethal TBI (p\0.05). H-2Kb-neg M1 and M2
populations sorted from host spleens at day 6 after TLI/ATS +
BMT stimulated H-2Kb+CD4+Foxp3+ Treg but not H-
2Kb+CD4+CD25negFoxp3neg or H-2Kb+CD8+ effector proliferation
in 72-hr CFSE MLR with C57BL/6 splenocyte responders. Day 6
H-2Kb-neg M1 and M2 cells sorted from TLI/ATS + BMT-treated
STAT6-/- or IL-4Ra-/- BALB/c hosts were unable to induce H-
2Kb+CD4+Foxp3+ Treg proliferation in MLR, supporting an IL-4/
STAT6-inducible pathway by which these MDSC gain capacity to
induce Treg proliferation. Using hosts deficient in key IL-4/
STAT6-inducible proteins (Arginase, NOS-2) in MDSC, we are
now delineating the MDSC pathway inducing Treg proliferation
and tolerance after TLI/ATS + BMT.504
HERPES SIMPLEX VIRUS INDUCED STEM CELL DIFFERENTIATION AND
ASSOCIATION WITH GRAFT-VERSUS-HOST DISEASE (GVHD) IN BONE
MARROW TRANSPLANT RECIPIENTS
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Viral pathogens have been implicated in the pathogenesis of
GVHD. Skin rash due to GVHD resembles herpes simplex virus(HSV)-associated erythema multiforme (EM), in which HSV-in-
fected CD34+ stem cells are stimulated to differentiate into antigen
presenting CD1a+ DCs which reside in the skin epidermis and are
known as Langerhans cells (LC). This differentiation involves
increased E-cadherin expression. HSV-primed LCs present HSV
protein to T-cells and lead to EM.
In this prospective study, we examined (1) HSV-induced CD34+
cell differentiation and (2) Expression of the HSV Pol gene in blood
MNC and tissue samples of allogeneic SCT patients obtained before
and after the transplant. HSV prophylaxis was oral acyclovir. Second
skin biopsy was obtained only from patients who developed a rash
posttransplant. Double immunofluorescent staining and FACS anal-
ysis were used to quantify the expression of the HSV antigen (Pol),
CD34 and differentiation-associated markers (e.g., E-cadherin).
A total of 35 patients were enrolled. Data are available in 27 pa-
tients. Twenty-two (81%) had negative pol, CD34/pol, CD14/pol,
CD11b/pol, CD1a/pol immunostaining in the skin at baseline.
Group I: Twelve patients, 7 male, developed GVHD. In this group,
11 (92%) patients became pol+ and 9 had CD34+/pol+ in the skin.
Nine out of 11 (82%) patients had increased number of CD34+/
Pol+ expressing PBMNCs. Seven out of 11 (64%) and 6 out of 7
(86%) patients had increased CD34+/E-cad+ and CD1a+/Pol+
PBMNCs, respectively. Group II: Six patients (22%), all male, devel-
oped rash but no provenGVHD.Only 2 out of 4 patients (50%) with
non-GVHD rash were pol+ in the skin post-SCT. Level of antigen
expression in this group all decreased post-SCT blood samples.
Group III: Eleven patients, 7 of them female, had no rash post-
SCT and all of them remained pol-negative in blood samples
post-transplant. Four patients (36%) had slight increase in CD34+/
Pol+ expressing PBMNCs compared to baseline. CD34+/E-cad+
cells were noted to be minimally increased in 2 patients (18%) only.
In conclusion, our data suggest that HSV can be reactivated at the
cellular level after allogeneic SCT and appears be associated with the
occurrence of skin GVHD. Differentiated LCs in the skin following
HSV infection of the circulating CD34+ cells may well be part of this
association. Additional studies are warranted to confirm these results
and consider new strategies to prevent GVHD, including perhaps
more intense HSV prophylaxis.505
DOUBLE HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTA-
TION (HSCT) RESULTS IN SUCCESSFUL ENGRAFTMENT OF BONE MAR-
ROW FROM BOTH DONORS WITHOUT GRAFT VERSUS HOST OR GRAFT
VERSUS GRAFT EFFECTS
Biswas, C., Sauter, C., Grosso, D., Flomenberg, N., Alpdogan, O. Kimmel
Cancer Center, Thomas Jefferson University, Philadelphia, PA
We hypothesize that the use of two haploidentical donors, each
targeting a different recipient haplotype, will increase anti- leukemia
activity after double haploidentical SCT.We first established a hap-
loidentical transplantmodel using two different hybridmouse strains
as donor and recipient in the experiments. Lethally irradiated
B6CBAF1 (H2Kb/k) recipients were transplanted with T cell de-
pleted (TCD) bone marrow (BM) from B6D2F1 (H2Kb/d) donors.
Recipient mice harvested at days 28, 42 and 84, showed more than
90%donor cell engraftment, including donor derived lymphopoiesis
and myelopoiesis, without evidence of graft versus host disease.
Subsequently, lethally irradiated B6CBAF1 (H2Kb/k) recipients
were transplanted with TCD-BM from two haploidentical donors
(DH model) including B6SJLF1 (H2Kb/s) (donor 1 - D1) and
B6D2F1 (H2Kb/d) (donor 2 - D2). We observed recipients for 90
days and all mice survived without evidence of GVHD or weight
loss. Analyses of blood collected retro-orbitally at day 90 revealed
that recipients of DH transplants had significantly higher WBC
and neutrophil counts than recipients of SH HSCT from either
D1 orD2 respectively. DH recipients consistently showed successful
engraftment with mixed chimerism in both bone marrow and spleen.
We then explored the effects of low dose T cell infusions (1x105) on
chimerism of donor cells. Low doseT cell infusion from eitherD1 or
D2 did not affect the BM cellularity, but did increase the degree of
dominance of that donor’s cells in the BM and spleen.
Recipients of TCDDH transplants were challengedwith P815 tu-
mor cells. We used B6SJLF1 (D1) + B6CBAF1 (D2)/ B6D2F1
model in tumor experiments. Interestingly, recipients of TCD-DH
Poster Session II S335HSCT exhibited a significantly better survival than recipients of D1
SH or D2 SH transplants. However, after a low dose T cell infusion
(1 x105), recipients of D2 BM survived significantly better than recip-
ients of D1BM. In contrast to theTCDmodel, recipients ofDHBM
+ DH T cells show similar probability of survival with recipients of
D2 SH BM + D2 SH T. These data suggest that T cells from
B6SJLF1 have less anti-tumor activity than B6CBAF1 T cells.
We conclude that TCD DH HSCT results in successful engraft-
ment of both types of BM cells. Additionally, infusion of low dose
haploidentical T cells improves the anti-tumor effect without
stimulating GVHD. Double haploidentical HSCT may be an ideal
platform to enhance GVL effects after transplantation.506
WHOLE GENOME ANALYSIS OF CANDIDATE MINOR HISTOCOMPATIBIL-
ITY ANTIGENS PREDICTS A SMALL NUMBER OF COMMON, TIGHT-BIND-
ING EPITOPES TO HLA-A AND B SUPERTYPES
Randall, T.A.1, Hunsucker, S.A.2, Armistead, P.M.2 1National Institute
of Environmental Health Sciences, Durham, NC; 2University of North
Carolina, Chapel Hill, NC
Minor histocompatibility antigens (mHAs) mediate much of the
graft vs. leukemia (GvL) effect and graft vs. host disease (GvHD).
Immune responses to mHAs often result from disparities between
donor and recipient non-synonymous, coding, single-nucleotide
polymorphisms (cSNPs). Using high density DNA microarrays,
we associated genetic predictors of an mHA response (gIR) with ev-
idence of a clinical immune response (cIR), GvHD and or long-term
remission, and identified a novel, common mHA, T4A. Because of
multiple testing of large numbers of cSNPs and the statistical power
limitations caused by a relatively small number of SCT patients in
the cSNP analysis, we observed a high false positive prediction rate
with 40 cSNPs being screened to yield T4A. The purpose of our cur-
rent work is to develop a bioinformatics pipeline to identify all of the
cSNPs that could yield common mHAs from a large genomics
dataset, therebyminimizing the sample size and statistical limitations
encountered by high density DNA microarray methodologies.
We downloaded all cSNPs with a minor allele frequency $ 0.1
from CEU population of The HapMap Genome Browser Release-
27 and selected the alleles with a predicted minor mismatch
probability P(gIR)$ 0.16. The cSNPs were mapped to their known
flanking amino-acid sequences and were analyzed using the IEDB
ANN algorithm for binding to class I HLA supertypes using a cutoff
IC50\ 200 nM.
Of the 11,887 alleles evaluated, 2,240 encoded a peptide that could
be presented in at least 1HLA-A supertype, and 1,811 encoded a pep-
tide that could be presented in at least 1 HLA-B supertype. Many of
the examined alleles encoded peptides that could be presented by
several HLA supertypes, resulting in a total of 5,053 HLA-A super-
type epitopes and 3,060 HLA-B supertype epitopes being predicted.
We tested our method’s predictive ability by measuring binding of
92 of the predicted HLA-A02 supertype epitopes to HLA-A0201
using the iTopia Epitope Discovery System. Ninety percent of our
predicted epitopes bound to HLA-A0201 using this assay. Most epi-
topes predicted to have an IC50\50 nM had an HLA-dissociation
t1/2 . 8 hours (P0.0170).
Out of the 4,030,560 cSNPs in the HapMap set, our method pre-
dicted a relatively small number of epitopes that are likely to have
strong binding affinity to HLA molecules. By applying this method
to a large patient cohort the chances of identifying common, clini-
cally significant mHAs should be greatly enhanced.507
INCREASED PRODUCTION OF THE INFLAMMATORY CYTOKINE IL12P70
BY ACTIVATED HUMAN BLOOD DENDRITIC CELLS IS ASSOCIATED
WITH INCREASED SEVERITY OF ACUTE GRAFT VS HOST DISEASE POST
ALLOGENEIC STEM CELL TRANSPLANTATION
Sartor,M.1, Lau, J.1, Gottlieb, D.2, Bradstock, K.2 1WestmeadMillenium
Institute, Sydney, NSW, Austria; 2Westmead Hospital, Sydney, NSW,
Australia
Introduction: The activation status of peripheral blood CD11c+
myeloid dendritic cells (DC) as assessed by CMRF-44 antigen ex-pression is highly associated with the severity of acute GvHD
(Transplantation 2007;83: 839–846). However, very little is known
about the function of post transplantDC.We examined the relation-
ship between DC functional properties and the severity of acute
GvHD.
Method: Peripheral blood CD11c+ myeloid DC from 12 patients
were studied weekly up to 8 weeks post transplant for production
of IL2, IL4, INFg, IL10 and IL12 using an intracellular cytokine
flow assay. Mixed lymphocyte reactions were used to assess alloge-
neic immune responses in 5 patients.
Results: IL12 was the only cytokine detected in post transplant
DC. Five of 12 patients developed moderate to severe aGvHD
(grade II-IV), the remaining 7 patients developed either no
aGvHD or only grade I. In comparison with pre-transplant
levels of expression, patients with grade 11-1V had up to 4
fold higher percentage of CD11c+ DC expressing IL12 (median
15.1%, range 11.2-20.9%) as compared to patients with grade
0-1 aGvHD in whom there was no change from baseline values
(median 6.6% range 2.8-8.9%) p 5 0.0025. Increased expression
of IL12 was observed in CD11c+ DC commencing at day 25
post transplant. Interestingly, analysis of paired samples from
5 patients comparing sorted DC from donors with sorted DC
from peripheral blood of transplant patients at day +30 post-
transplant showed a marked reduction in the capacity of
post-transplant donor DCs to stimulate 3rd party lymphocyte
proliferation. None of these patients developed clinically signif-
icant aGvHD.
Conclusion: production of IL-12p70 by CD11c+ myeloid
DC correlates with severity of GvHD despite apparent defects
in the capacity of these cells to elicit 3rd party proliferative
responses.508
DEVELOPMENT OF AN ONLINE TOOL TO SCAN SINGLE NUCLEOTIDE
POLYMORPHISMS FOR IDENTIFICATION OF NOVEL MINOR HISTOCOM-
PATIBILITY ANTIGENS
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Minor histocompatibility antigens (mHags) are the molecular
targets of allo-immunity responsible both for the development
of antitumor effects and for graft-versus-host disease (GVHD)
in allogeneic hematopoietic stem cell transplantation (allo-
HSCT). Recently, we have reported that the large data set from
the International HapMap Project can be directly used for genetic
mapping of novel mHags when combined with conventional
immunologic assays such as interferon-gamma enzyme linked
immunosorbent assay (ELISA) or chromium release assay. The
target mHag locus can be uniquely mapped through whole ge-
nome association scanning based on immunologically-determined
mHag status in HapMap Epstein Barr virus-transformed (EBV)-
LCL panels transduced with retroviruses encoding predetermined
restriction HLA allele cDNAs. Once stably transduced, they are
easily maintained or cryopreserved for future use as screening
panels.
We have constructed an online interactive program to search
for single nucleotide polymorphisms (SNPs) responsible for not
only mHag generation but also specific cell phenotypes (e.g. sen-
sitivity or resistance to given drugs) by simply selecting ‘‘pheno-
type-positive’’ or ‘‘phenotype-negative’’ in a pull-down menu for
individual HapMap EBV-LCLs shown in the entry page. Three
data sets from CEU, JPT and CHB will be ready for use. A list
of candidate SNPs will be shown in a new page. The website
will be available as ‘‘HapMap Scanner’’ in the near future.
Thus, once suitable assays are generated, this method should
substantially facilitate discovery of novel SNPs applicable to
identifying patients who can benefit from SNP-based customized
therapies.
